Skip to main content
man with glasses and a flannel shirt looking up as he climbs ladder.

Referral information

Explore referral best practices for AFib patients that can't, won't or shouldn't take long-term OACs.

Oral anticoagulants (OACs) remain an effective and important stroke-risk reduction option for patients with atrial fibrillation (AFib). But they aren't right for everyone. Some AFib patients may encounter challenges with adherence to long-term OACs, which may signal the need for an alternative. Consider the WATCHMAN Left Atrial Appendage Closure (LAAC) Implant; a proven, safe, and effective alternative for eligible AFib patients who can't, won't, or shouldn't take long-term OACs.

Designed to treat a broad range of eligible patients with AFib including but not limited to those who:*

Can't Take OACs: Drug interactions, history of bleeding

History of bleeding

  • History of major and/or non-major bleeding

Drug interactions

  • Not suitable for long-term OACs due to contraindications with other medications

 

Won't Take OACs: Non-compliant/adherent, occupation and activities

Non-compliant/adherent

  • Skips/splits doses or discontinues OACs due to side effects, cost, cognitive impairment, procedural interruptions, or other barriers

Occupation and activities

  • Profession or lifestyle for which anticoagulation is inappropriate
Shouldn't take OACs: At risk for bleeding

At risk for bleeding

  • No prior bleeds but high-risk based on HAS-BLED or CHA₂DS₂-VASc scores; includes fall risk

 

 

 

Identify which of your AFib patients may benefit from the WATCHMAN Implant

The WATCHMAN Implant may be suitable for a broad range of non-valvular atrial fibrillation (AFib) patients and may be an appropriate option for those who:

  1. Are at increased risk for stroke based on CHA2DS2-VASc scores and are recommended for anticoagulation therapy†

  2. Are suitable for short-term anticoagulation therapy‡

  3. Have an appropriate rationale to seek a non-pharmacologic alternative to anticoagulation therapy
    Note: Does not apply to patients who receive the WATCHMAN Implant concomitantly or sequentially with an AFib ablation**
    Coverage remains unchanged. Under the CMS NCD, the patient must be deemed unable to take long-term OAC and meet all criteria in NCD 20.34 to be eligible for coverage. Commercial payer coverage policy requirements will vary.

Leverage our patient screening tools to determine your AFib patients' eligibility.

images of four diverse people

WATCHMAN patient referral process overview

An orange lightbulb icon.

1. Educate

Discuss benefits and risks of the WATCHMAN Implant, review procedure details, and share next steps for connecting with an implanting physician.


An orange document icon.

2. Document

Document your consultation using the Patient Screening Form, the Digital Patient Screening Tool, and input an eligibility summary into the patient's medical record (depending on the implanting physicians' preferred method). This supplies the implanting physician access to all referral information.


An orange mouse cursor icon.

3. Send

Send referral to the implanting physician, according to that physician's requirements.

Learn how WATCHMAN has positively impacted patients' quality of life

Patient perspective

Getting a WATCHMAN Implant has made a huge difference in Wayne’s life. Being very active, he immediately knew that the risks and side effects of blood thinners would hold him back from the life he wanted to live. After his implant procedure, he’s back to yoga, hiking, and volunteering — all without the worries of bleeding or stroke. 

Cardiologist perspective

Cardiologists describe the impact WATCHMAN has had on their patients. Hear how after receiving the WATCHMAN Implant, patients were able to go back to their everyday activities without the worry of OAC bleed risk. Hear more about the different patient types who were candidates for the WATCHMAN Implant. 

Explore examples of WATCHMAN candidates


*Documentation supporting medical necessity is required for coverage. Example clinical scenarios that may support consideration of alternatives to long-term oral anticoagulation are described in the 2015 ACC/HRS/SCAI consensus public comment referenced in the CMS LAAC Decision Memorandum and should be considered in conjunction with the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.

†Increased Risk = CHA₂DS₂-VASc ≥ 2 in men, ≥ 3 in women. CMS coverage criteria requires a CHA₂DS₂-VASc score ≥ 3. Providers are encouraged to read the decision memo in its entirety for additional detail

‡Option for immediate DAPT-only post-implant drug regimen for standalone WATCHMAN procedures.

**In the OPTION trial, sequential LAAC was a minimum of 90 days post AFib ablation (as a protocol-driven blanking period).